Publisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment

• Jonathan I. Silverberg,
• Andreas Wollenberg,
• Linda Stein Gold,
• James Del Rosso,
• Gil Yosipovitch,
• Peter Lio,
• Jose-Manuel Carrascosa,
• Gaia Gallo,
• Yuxin Ding,
• Zhenhui Xu,
• Marta Casillas,
• Evangeline Pierce,
• Helena Agell,
• Sonja Ständer

Affiliations

Jonathan I. Silverberg

George Washington University School of Medicine

Andreas Wollenberg

Department of Dermatology and Allergy, University Hospital Augsburg

Linda Stein Gold

Henry Ford Health System

James Del Rosso

JDR Dermatology Research

Gil Yosipovitch

Miller School of Medicine, University of Miami

Peter Lio

Northwestern University Feinberg School of Medicine

Jose-Manuel Carrascosa

Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, IGTP

Gaia Gallo

Eli Lilly and Company

Yuxin Ding

Eli Lilly and Company

Zhenhui Xu

CIMS Global LLC

Marta Casillas

Eli Lilly and Company

Evangeline Pierce

Eli Lilly and Company

Helena Agell

Almirall S.A.

Sonja Ständer

Center for Chronic Pruritus and Department of Dermatology, University Hospital Münster